Supplement_Table_S2 – Supplemental material for Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement
Tzong-Yun Ger
Yu-Huei Huang
Rosaline Chung-yee Hui
Tsen-Fang Tsai
Hsien-Yi Chiu
10.25384/SAGE.8010734.v1
https://sage.figshare.com/articles/journal_contribution/Supplement_Table_S2_Supplemental_material_for_Effectiveness_and_safety_of_secukinumab_for_psoriasis_in_real-world_practice_analysis_of_subgroups_stratified_by_prior_biologic_failure_or_reimbursement/8010734
<p>Supplemental material, Supplement_Table_S2 for Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement by Tzong-Yun Ger, Yu-Huei Huang, Rosaline Chung-yee Hui, Tsen-Fang Tsai and Hsien-Yi Chiu in Therapeutic Advances in Chronic Disease</p>
2019-04-17 12:00:00
biologic failure
real-world
reimbursement
secukinumab
tumor necrosis factor-α inhibitors
ustekinumab